Expression and clinical significance of programmed death‑1 on lymphocytes and programmed death ligand‑1 on monocytes in the peripheral blood of patients with cervical cancer
- Ying Zhang
- Weipei Zhu
- Xueguang Zhang
- Qiuxia Qu
- Liyuan Zhang
Published online on: September 29, 2017
Copyright: © Zhang et al.
This is an open access article distributed under the terms of Creative Commons Attribution License.
The programmed death‑1 (PD‑1) signaling pathway serves a critical role in immune regulation and tolerance by suppressing the activation and proliferation of T cells. The aim of the present study was to investigate the effect of PD‑1 and programmed death‑ligand 1 (PD‑L1) on the development of cervical carcinoma and cervical intraepithelial neoplasia (CIN). A total of 40 healthy controls (HC), 40 patients with CIN and 66 newly diagnosed cervical cancer patients were recruited. The expression level of PD‑1 expression on peripheral cluster of differentiation (CD)4+ and CD8+ T cells and PD‑L1 on monocytes was analyzed by flow cytometry. The expression level of soluble PD‑L1 in serum was determined by an ELISA. The results of the present study demonstrated that the PD‑1 expression level on CD4+ and CD8+ T cells was significantly increased in CIN and cervical cancer, compared with that in HC. In addition, the PD‑1 expression level on CD4+ and CD8+ T cells was increased in cervical cancer, compared with that in CIN. However, the expression level of PDL‑1 on CD14+ monocytes was increased in cancer and CIN, but limited in cancer and CIN. In addition, PD‑1 expression on CD4+ T cells was positively associated with PD‑1 expression on CD8+ T cells in cervical cancer (P<0.05). Further analyses revealed that the proportion of PD‑1 on CD4+ and CD8+ T cells were positively associated with tumor stages. However, no difference in the degree of soluble PD‑1 among cancer, CIN and HC cells was revealed. The results suggested that the PD‑1 signaling pathway is involved in the development of CIN and cervical cancer.